Hivandron Injection (Ibandronic Acid Sodium Hydrate)

Adult administration

3 mg intravenously every 3 months over 15 - 30 seconds.

This medication must be administered intravenously and care should be taken to avoid injecting into arteries or around the veins, as this may cause tissue damage. It should not be administered to patients who are allergic to this drug or its components and to untreated hypocalcemia patients. In clinical trials with long-term use of this drug, side effects such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, headache, rash, and fatigue have been reported. When administered via injection, temporary flu-like symptoms (arthralgia, myalgia, fever, chills, fatigue, etc.) may occur but most are mild and resolve without treatment. Before administering this medication, it is important to treat hypocalcemia and metabolic disorders of bones and minerals, and to ensure adequate intake of calcium and vitamin D. During osteoporosis treatment, severe bone, joint, and muscle pain may occur, and if symptoms arise, immediate consultation with healthcare professionals is required. Reports of osteonecrosis of the jaw have been noted; therefore, especially in cancer patients or those needing dental treatment, an oral examination should be conducted before administration, and excessive dental interventions should be avoided during treatment. This drug is not metabolized by the liver and is excreted via the kidneys, so patients with impaired kidney function require regular monitoring. Women who are pregnant or breastfeeding should avoid using this drug, as its safety has not been established. In cases of overdose, careful monitoring is necessary as it may affect kidney and liver function, and appropriate treatment is needed if hypocalcemia or other complications arise. This medication should not be mixed with calcium-containing solutions, and syringes and needles should not be reused and must be disposed of safely.

Serious side effects

Hives, angioedema, facial swelling/edema, anaphylaxis/shock, hypersensitivity, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, osteonecrosis (jaw, external auditory canal), acute renal failure, respiratory distress, multiple organ failure, death

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• dyspepsia
• nausea
• constipation
• musculoskeletal pain
• arthralgia
• myalgia
• flu-like symptoms

This medication should be stored in a sealed container to protect it from air exposure and is best kept at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent deterioration.

Appearance

A colorless, transparent solution in a colorless, transparent glass prefilled syringe, with a single-use syringe needle attached.

Package unit

3 milliliters/prefilled syringe